Shots:

• The P-III ALEX study involves assessing of Alecensa vs crizotinib in 303 treatment-naïve patients in a ratio (1:1) with ALK+ NSCLC whose tumors were characterized as ALK+ by the VENTANA ALK (D5F3) CDx Assay
• Updated results: OS @5yrs. (62.5% vs 45.5%); reduction in the risk of death in patients with/ without CNS metastases (42%/ 24%) respectively- updated data confirms Alecensa’s safety & tolerability. The updated data follows mPFS data- presented at ESMO 2019 which demonstrated 57% reduction in risk of disease worsening or death
• Alecensa (RG7853/AF-802/RO5424802/CH5424802) is a highly selective- CNS active- oral therapy- being developed for people with ALK+ NSCLC and has received approval in 88+ countries as 1L treatment for ALK+ m-NSCLC including in the US- EU- Japan and China

 ­ Ref: Roche | Image: Roche